



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**  
(Case No. 03-769)

In the Application of:

Enno Adema

Serial No.: 10/652,372

Filing Date: 08/29/2003

For: Improvement of Specificity in the  
Determination of Antithrombin

)  
)  
) Before the Examiner: Not yet assigned  
)  
)  
) Art Unit: 1641  
)  
)  
)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

In regard to the above identified application:

1. We are transmitting herewith the attached:
2. a. Form PTO-1449 and 10 cited references;  
b. Postcard.
3. No Fee is required.
4. Please charge any additional fees or credit overpayment to Deposit Account No.13-2490.

Respectfully submitted,

McDONNELL BOEHNEN  
HULBERT & BERGHOFF

Patrick G. Gattari  
Reg. No. 39,682

McDONNELL BOEHNEN  
HULBERT & BERGHOFF  
300 SOUTH WACKER DRIVE  
CHICAGO, ILLINOIS 60606

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 17 day of February 2004.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

03-769

Serial No.

10/652,372

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)



Applicant:

Enno Adema

Filing Date:

August 29, 2003

Group:

#

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	5,891,647	04/06/1999	Lormeau, et al			
	5,320,945	06/14/1994	Dessauer, et al			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	EP 0 657 547 A1	06.14.1995	PCT				
	EP 0 927 767 A2	07.07.1999	PCT				
	EP 0 391 433	10.10.1990	PCT				
	JP 06094713 (abstract)	08.04.1994	JP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	Topper, M., et al., <i>Enzyme-linked immunosorbent assay for thrombin-antithrombin III complexes in horses</i> ; AJVR, 57(4):427-431 (1996).
	Ruzzenente, O., et al., <i>Use of Purified Dermatan Sulfate for heparin Cofactor II (HC II) Assay</i> ; Thrombosis Research; 65:281-287 (1992).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



**Atty. Docket No.**

03-769

**Serial No.**

10/652,372

**Applicant:**

Enno Adema

**Filing Date:**

August 29, 2003

**Group:**

#

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

		Pelzer, H., <i>et al.</i> , <i>Determination of Human thrombin-Antithrombin II Complex in Plasma with an Enzyme-Linked Immunosorbent Assay</i> ; Thrombosis and Haemostasis, 59(1):101-106 (1988).
		Demers, C., <i>et al.</i> , <i>An Antithrombin III Assay Based on Factor Xa Inhibition Provides a More Reliable Test to Identify Congenital Antithrombin III Deficiency Than an Assay Based on Thrombin Inhibition</i> "; Thrombosis and Haemostasis; 69(3):231-235 (1993).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.